Less than 3 doses of the HPV vaccine – Review of efficacy against virological and disease end points

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 6, 2016, Pages 1394-1402

  Basu, Partha ^a   Bhatla, Neerja ^b   Ngoma, Twalib ^c   Sankaranarayanan, Rengaswamy ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

cervical cancer; cervical intraepithelial neoplasia; genital wart; human papillomavirus; incident infection; persistent infection; review; single dose; two doses; vaccine

Indexed keywords

VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

CHILD; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WORLD HEALTH ORGANIZATION; CASE CONTROL STUDY; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; VIROLOGY;

CASE-CONTROL STUDIES; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME;

EID: 84964043480     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1146429     Document Type: Review

References (35)

1. K.K.Smolen, L.Gelinas, L.Franzen, S.Dobson, M.Dawar, G.Ogilvie, M.Krajden, E.S.Fortuno, III, T.R.Kollmann. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012; 30:3572-79; PMID:22469863; http://dx.doi.org/10.1016/j.vaccine.2012.03.051
2. J.T.Schiller, X.Castellsague, S.M.Garland. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(Suppl 5):F123-38; PMID:23199956; http://dx.doi.org/10.1016/j.vaccine.2012.04.108
3. C.Pedersen, T.Petaja, G.Strauss, H.C.Rumke, A.Poder, J.H.Richardus, B.Spiessens, D.Descamps, K.Hardt, M.Lehtinen, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-71; PMID:17531764; http://dx.doi.org/10.1016/j.jadohealth.2007.02.015
4. B.Romanowski, T.F.Schwarz, L.M.Ferguson, K.Peters, M.Dionne, K.Schulze, B.Ramjattan, P.Hillemanns, G.Catteau, K.Dobbelaere, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7:1374-86; PMID:22048171; http://dx.doi.org/10.4161/hv.7.12.18322
5. M.Krajden, D.Cook, A.Yu, R.Chow, W.Mei, S.McNeil, D.Money, M.Dionne, K.P.Karunakaran, J.M.Palefsky, et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 2011; 18:418-23; PMID:21248158; http://dx.doi.org/10.1128/CVI.00489-10
6. S.R.Dobson, S.McNeil, M.Dionne, M.Dawar, G.Ogilvie, M.Krajden, C.Sauvageau, D.W.Scheifele, T.R.Kollmann, S.A.Halperin, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802; PMID:23632723; http://dx.doi.org/10.1001/jama.2013.1625
7. E.Lazcano-Ponce, M.Stanley, N.Munoz, L.Torres, A.Cruz-Valdez, J.Salmeron, R.Rojas, R.Herrero, M.Hernandez-Avila. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014; 32:725-32; PMID:24355090; http://dx.doi.org/10.1016/j.vaccine.2013.11.059
8. A.R.Kreimer, A.C.Rodriguez, A.Hildesheim, R.Herrero, C.Porras, M.Schiffman, P.Gonzalez, D.Solomon, S.Jimenez, J.T.Schiller, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-51; PMID:21908768; http://dx.doi.org/10.1093/jnci/djr319
9. R.Sankaranarayanan. HPV vaccination: The most pragmatic cervical cancer primary prevention strategy. Int J Gynaecol Obstet 2015; 131(Suppl 1):S33-35; PMID:26433502; http://dx.doi.org/10.1016/j.ijgo.2015.02.014
10. World Health Organization. Evidence based recommendations on Human Papilloma Virus (HPV) Vaccines Schedules. Background paper for SAGE discussions. http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf. 2014.
11. R.Donken, M.J.Knol, J.A.Bogaards, F.R.van der Klis, C.J.Meijer, H.E.de Melker. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis. J Infect 2015; 71:61-73; PMID:25709084; http://dx.doi.org/10.1016/j.jinf.2015.02.005
12. S.L.Block, T.Nolan, C.Sattler, E.Barr, K.E.Giacoletti, C.D.Marchant, X.Castellsague, S.A.Rusche, S.Lukac, J.T.Bryan, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-45; PMID:17079588; http://dx.doi.org/10.1542/peds.2006-0461
13. V.Gilca, C.Sauvageau, N.Boulianne, S.G.De, M.Couillard, M.Krajden, M.Ouakki, D.Murphy, A.Trevisan, M.Dionne. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9–10 year-old girls according to 0-6 month schedule. Hum Vaccin Immunother 2014; 10:2438-45; PMID:25424952; http://dx.doi.org/10.4161/hv.29617
14. F.X.Bosch, T.R.Broker, D.Forman, A.B.Moscicki, M.L.Gillison, J.Doorbar, P.L.Stern, M.Stanley, M.Arbyn, M.Poljak, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31(Suppl 8):I1-31; PMID:24229716; http://dx.doi.org/10.1016/j.vaccine.2013.07.026
15. T.F.Leung, A.P.Liu, F.S.Lim, F.Thollot, H.M.Oh, B.W.Lee, L.Rombo, N.C.Tan, R.Rouzier, D.Friel, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Hum Vaccin Immunother 2015; 11:1689-702; PMID:26062002; http://dx.doi.org/10.1080/21645515.2015.1050570
16. M.Boxus, L.Lockman, M.Fochesato, C.Lorin, F.Thomas, S.L.Giannini. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine 2014; 32:3232-6; PMID:24731816; http://dx.doi.org/10.1016/j.vaccine.2014.04.005
17. R.Sankaranarayanan, P.R.Prabhu, M.Pawlita, T.Gheit, N.Bhatla, R.Muwonge, B.M.Nene, P.O.Esmy, S.Joshi, U.R.R.Poli, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncology 2015. (In press).
18. A.R.Kreimer, F.Struyf, M.R.Del Rosario-Raymundo, A.Hildesheim, S.R.Skinner, S.Wacholder, S.M.Garland, R.Herrero, M.P.David, C.M.Wheeler. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015; 16:775-86; PMID:26071347; http://dx.doi.org/10.1016/S1470-2045(15)00047-9
19. A.Hildesheim, S.Wacholder, G.Catteau, F.Struyf, G.Dubin, R.Herrero. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014; 32:5087-97; PMID:25018097; http://dx.doi.org/10.1016/j.vaccine.2014.06.038
20. European Medicines Agency. Assessment report: Cervarix. International non-proprietary name: Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed). 2013.
21. K.Kavanagh, K.G.Pollock, A.Potts, J.Love, K.Cuschieri, H.Cubie, C.Robertson, M.Donaghy. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014; 110:2804-11; PMID:24736582; http://dx.doi.org/10.1038/bjc.2014.198
22. S.M.Garland, M.Steben, H.L.Sings, M.James, S.Lu, R.Railkar, E.Barr, R.M.Haupt, E.A.Joura. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805-14; PMID:19199546; http://dx.doi.org/10.1086/597071
23. B.Donovan, N.Franklin, R.Guy, A.E.Grulich, D.G.Regan, H.Ali, H.Wand, C.K.Fairley. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44; PMID:21067976; http://dx.doi.org/10.1016/S1473-3099(10)70225-5
24. M.Blomberg, C.Dehlendorff, C.Munk, S.K.Kjaer. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013; 57:929-34; PMID:23804192; http://dx.doi.org/10.1093/cid/cit436
25. S.N.Tabrizi, J.M.Brotherton, J.M.Kaldor, S.R.Skinner, E.Cummins, B.Liu, D.Bateson, K.McNamee, M.Garefalakis, S.M.Garland. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206: 1645-51; PMID:23087430; http://dx.doi.org/10.1093/infdis/jis590
26. H.Ali, B.Donovan, H.Wand, T.R.Read, D.G.Regan, A.E.Grulich, C.K.Fairley, R.J.Guy. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346:f2032; PMID:23599298; http://dx.doi.org/10.1136/bmj.f2032
27. E.Herweijer, A.Leval, A.Ploner, S.Eloranta, J.F.Simard, J.Dillner, E.Netterlid, P.Sparen, L.Arnheim-Dahlstrom. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014; 311:597-603; PMID:24519299; http://dx.doi.org/10.1001/jama.2014.95
28. E.Crowe, N.Pandeya, J.M.Brotherton, A.J.Dobson, S.Kisely, S.B.Lambert, D.C.Whiteman. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014; 348:g1458; PMID:24594809; http://dx.doi.org/10.1136/bmj.g1458
29. D.M.Gertig, J.M.Brotherton, A.C.Budd, K.Drennan, G.Chappell, A.M.Saville. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013; 11:227; PMID:24148310; http://dx.doi.org/10.1186/1741-7015-11-227
30. J.M.L.Brotherton, M.Malloy, A.C.Budd, M.Saville, K.T.Drennan, D.M.Gertig. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Research 2015; 1:59-73; http://dx.doi.org/10.1016/j.pvr.2015.05.005
31. E.A.Joura, S.K.Kjaer, C.M.Wheeler, K.Sigurdsson, O.E.Iversen, M.Hernandez-Avila, G.Perez, D.R.Brown, L.A.Koutsky, E.H.Tay, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51; PMID:18930097; http://dx.doi.org/10.1016/j.vaccine.2008.09.073
32. IARC. Primary end-points for prophylactic HPV Vaccine Trials: IARC Working Group Report Volume 7. 2014.
33. D.S.Lamontagne, V.D.Thiem, V.M.Huong, Y.Tang, K.M.Neuzil. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis 2013; 208:1325-34; PMID:23901077; http://dx.doi.org/10.1093/infdis/jit363
34. J.W.Wang, C.F.Hung, W.K.Huh, C.L.Trimble, R.B.Roden. Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila) 2015; 8:95-104; PMID:25488410; http://dx.doi.org/10.1158/1940-6207.CAPR-14-0311
35. J.Paavonen, P.Naud, J.Salmerón, C.M.Wheeler, S.N.Chow, D.Apter, H.Kitchener, X.Castellsague, J.C.Teixeira, S.R.Skinner, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet. 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4